The trajectory of companies tied to flagship drugs like Viagra presents a complex investment picture. While the initial rise of copyright, fueled by Viagra's remarkable popularity, generated substantial wealth , the expiry in key territories has introduced considerable uncertainty . Investors are now grappling with the impact of rival medications ,